MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma
Received 8 November 2019
Accepted for publication 11 February 2020
Published 26 February 2020 Volume 2020:12 Pages 1427—1435
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Eileen O'Reilly
Shiheng Jia, 1–4 Minghui Zhang, 1–4 Yanshu Li, 1–3 Lan Zhang, 5 Wei Dai 5
1Key Laboratory of Cell Biology, Ministry of Public Health, China Medical University, Liaoning, Shenyang 110122, People’s Republic of China; 2Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Liaoning, Shenyang 110122, People’s Republic of China; 3Department of Cell Biology, China Medical University, Liaoning, Shenyang 110122, People’s Republic of China; 4Department of Clinical Medicine, China Medical University, Liaoning, Shenyang 110122, People’s Republic of China; 5Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Liaoning, Shenyang 110002, People’s Republic of China
Correspondence: Wei Dai
Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Liaoning, Shenyang 110002, People’s Republic of China
Background: Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer worldwide. Growing evidence showed that Melanoma-associated antigen-A11 (MAGE-A11) was abnormally expressed in various malignancies, but MAGE-A11 expression and its biological roles in HNSCC had not been reported in detail. The aim of the study was to investigate the association between MAGE-A11 signatures and clinicopathological features of HNSCC patients and uncover its potential mechanisms in HNSCC patients.
Methods: In the present study, we analyzed the expression of MAGE-A11 gene and evaluated the impact of MAGE-A11 genes expression on clinical outcome from the Cancer Genome Atlas (TCGA) database. MAGE-A11 expression was assessed in a well-characterized series of HNSCC (N = 75) with long-term follow-up and 10 cases of adjacent non-cancerous tissues, which were diagnosed between 2013 and 2014, by using immunohistochemistry. The correlation between MAGE-A11 expression and clinicopathological factors was analyzed. Kaplan–Meier and Cox regression analyses were used to assess the prognostic significance of MAGE-A11 expression among HNSCC patients.
Results: The results showed that MAGE-A11 mRNA expression was increased in HNSCC tissues compared to “normal” tissues (P < 10− 12). MAGE-A11 protein expression was not correlated with lymph node status, relapse, age, gender, histological grade, differentiation, clinical stage, tumor size, radiotherapy or chemotherapy. The patients with high MAGE-A11 expression had lower 5-year overall survival (OS) rates than those with low MAGE-A11 expression as determined using the Kaplan–Meier method. The univariate and multivariate analyses confirmed that elevated MAGE-A11 was an independent prognostic factor for the OS of HNSCC patients.
Conclusion: These findings indicate that MAGE-A11 may be a valuable diagnostic or prognostic marker as well as a potential molecular therapy target for HNSCC patients.
Keywords: Melanoma-associated antigen-A11, immunohistochemistry, head and neck squamous cell carcinoma, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]